Breast Cancer Liquid Biopsy Testing Devices Market to Grow with a CAGR of 17.20% through 2028
MRD monitoring, regulatory approvals, and industry
collaboration is expected to drive the Global Breast Cancer Liquid Biopsy
Testing Devices Market growth in the forecast period, 2024-2028.
According to TechSci Research report, “Breast
Cancer Liquid Biopsy Testing Devices Market – Global Industry Size, Share,
Trends, Competition Forecast & Opportunities, 2028”, the Global Breast
Cancer Liquid Biopsy Testing Devices Market stood at USD 835.36 million in 2022
and is anticipated to grow with a CAGR of 17.20% in the forecast period,
2024-2028. This can be attributed to personalized medicine. Personalized
medicine is an emerging trend in the healthcare industry, and breast cancer
liquid biopsy testing devices align perfectly with this approach. These devices
allow healthcare professionals to tailor treatment plans to the individual
genetic makeup of the patient's tumor. Mutational analysis of liquid biopsy
results enables the identification of specific genetic alterations in a
patient's tumor, which, in turn, aids in the selection of the most effective
targeted therapies. The move towards personalized treatment options is a strong
catalyst for the growth of this market.
Furthermore, with the collection and analysis of
genetic data, there is a growing focus on ethical and data privacy concerns.
Ensuring the secure handling of patients' genetic information is a trend that
will continue to gain attention. The development of strict data protection
measures is crucial to address these concerns.
Liquid biopsy serves as a valuable asset in the realm
of breast cancer diagnosis and treatment. The analysis of mutations through
liquid biopsy aids in the identification of targeted therapies tailored to
individual patients based on their tumor-specific genetic alterations. To
illustrate, in the case of patients grappling with metastatic breast cancer,
screening for the PIK3CA mutation, which is found in around 40% of HR-positive
tumors, assists in determining the most effective treatment path.
Furthermore, the potential for identifying minimal
residual disease (MRD) via circulating tumor DNA in liquid biopsy holds
significant promise and can bring transformative advances to the field of
oncology. Additionally, an uptick in regulatory approvals is anticipated to
positively impact the market. For instance, in June 2019, the United States
Food and Drug Administration (FDA) granted regulatory clearance to QIAGEN's
therascreen PIK3CA RGQ PCR Kit. This clearance allowed the device to be used as
a companion diagnostic assay for detecting PIK3CA mutations in breast cancer,
covering both tissue and liquid biopsies.
The Global Breast Cancer Liquid Biopsy Testing Devices
Market is segmented into offerings, circulating biomarker, application,
regional distribution, and company.
Based on its offerings, the Instruments is poised to
capture a substantial market share in the Global Breast Cancer Liquid Biopsy
Testing Devices Market during the forecast period due to several key factors.
Firstly, the company's innovative and cutting-edge technology in liquid biopsy
testing has established it as a frontrunner in the industry. Their commitment
to research and development ensures that their products remain at the forefront
of technological advancements. Additionally, The Instruments' strategic
partnerships with leading healthcare institutions and its strong distribution
network have extended its market reach. This, combined with a reputation for
delivering accurate and reliable results, fosters trust among healthcare
professionals and patients alike. As the global demand for non-invasive and
early-stage cancer detection solutions continues to grow, The Instruments is
well-positioned to make a significant impact in this dynamic market segment.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "Global Breast Cancer Liquid Biopsy Testing Devices Market.”
Based on circulating biomarker, Circulating Tumor DNA
(ctDNA) is anticipated to secure a substantial market share in the Global
Breast Cancer Liquid Biopsy Testing Devices Market during the forecast period
for several compelling reasons. Firstly, ctDNA has emerged as a game-changer in
the field of cancer diagnostics, offering a non-invasive and highly sensitive
method for detecting breast cancer mutations. As advancements in liquid biopsy
technology continue to evolve, ctDNA has proven to be an efficient and reliable
choice, allowing for real-time monitoring of tumor progression and treatment
effectiveness. Its versatility in identifying a broad spectrum of genetic
alterations provides a competitive edge, as it caters to the personalized
medicine trend, aligning treatment strategies with a patient's unique genetic
profile. Furthermore, its acceptance in clinical practice is on the rise,
bolstered by an increasing body of evidence supporting its efficacy. As the
Global Breast Cancer Liquid Biopsy Testing Devices Market expands, the adoption
of ctDNA is set to witness substantial growth, making it a pivotal player in
the industry.
Major companies operating in Global Breast Cancer
Liquid Biopsy Testing Devices Market are:
- A Menarini AG
- NeoGenomics Laboratories Inc
- F Hoffmann-La Roche AG
- Myriad Genetics Inc
- QIAGEN NV
- Biocept Inc
- Sysmex Corp
- Fluxion Biosciences Inc
- Thermo Fisher Scientific Inc
- Epic Sciences Inc
Download Free Sample Report
Customers can also request for 10% free customization
on this report.
“The global breast cancer liquid biopsy testing
devices market is poised for significant growth, driven by emerging trends that
include personalized medicine, MRD monitoring, early detection, technology
advancements, integration with conventional diagnostics, telemedicine, ethical
considerations, and expanding clinical utility. As these trends continue to
evolve, liquid biopsy testing devices will become even more indispensable tools
in the fight against breast cancer, offering improved patient outcomes and more
efficient healthcare practices. The future holds great promise for this
innovative approach to breast cancer diagnosis and monitoring,” said Mr. Karan
Chechi, Research Director with TechSci Research, a research-based management
consulting firm.
“Breast Cancer Liquid Biopsy Testing Devices Market
By Offerings
(Assay & Reagents Kits, Instruments), By Circulating Biomarker (Circulating
Tumor DNA, Circulating Tumor Cell, Extracellular Vesicles), By Application
(Cancer Applications, Non-Cancer Applications), By
Region, By Competition Forecast & Opportunities, 2018-2028F”, has evaluated
the future growth potential of Global Breast Cancer Liquid Biopsy Testing
Devices Market and provides statistics & information on market size,
structure and future market growth. The report intends to provide cutting-edge
market intelligence and help decision makers take sound investment decisions.
Besides, the report also identifies and analyzes the emerging trends along with
essential drivers, challenges, and opportunities in Global Breast Cancer Liquid
Biopsy Testing Devices Market.
Contact
Techsci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel: +13322586602
Email: [email protected]
Website: www.techsciresearch.com